{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:36:37Z","timestamp":1780788997915,"version":"3.54.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s11912-020-00972-1","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T15:04:12Z","timestamp":1597676652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches"],"prefix":"10.1007","volume":"22","author":[{"given":"Mansi R.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin S.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"972_CR1","doi-asserted-by":"crossref","unstructured":"Eastwood-Wilshere N, Turner J, Oliveira N, Morton A. Cancer in pregnancy. Asia-Pacific J Clin Oncol. 2019.","DOI":"10.1111\/ajco.13235"},{"key":"972_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. J Clin Oncol. 2016;34(5):501\u20138. Expert consensus guidelines for management of hematologic malignancies in pregnancy focusing on optimal treatment of the mother, while protecting fetal and pediatric health.","DOI":"10.1200\/JCO.2015.62.4445"},{"issue":"4","key":"972_CR3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/theoncologist.2002-0279","volume":"7","author":"NA Pavlidis","year":"2002","unstructured":"Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7(4):279\u201387.","journal-title":"Oncologist"},{"key":"972_CR4","doi-asserted-by":"crossref","unstructured":"\u2022 Calsteren KV, Heyns L, Smet FD, Eycken LV, Gziri MM, Gemert WV, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. 2010. Comparison of obstetrical and neonatal outcomes of chemotherapy exposed patients versus unexposed patients diagnosed with invasive cancer during pregnancy, collected over a span of 20 years.","DOI":"10.1200\/JCO.2009.23.2801"},{"key":"972_CR5","doi-asserted-by":"crossref","unstructured":"Cottreau CM, Dashevsky I, Andrade SE, Li D-K, Nekhlyudov L, Raebel MA, et al. Pregnancy-associated cancer: a US population-based study. J Women's Health. 2019;28(2):250\u20137.","DOI":"10.1089\/jwh.2018.6962"},{"key":"972_CR6","doi-asserted-by":"crossref","unstructured":"Howdeshell KL, Shelby MD. Epidemiology of cancer in pregnancy. managing cancer during pregnancy: Springer; 2016. p. 3\u201316.","DOI":"10.1007\/978-3-319-28800-0_1"},{"issue":"4","key":"972_CR7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/jog.12597","volume":"41","author":"A El-Messidi","year":"2015","unstructured":"El-Messidi A, Patenaude V, Abenhaim HA. Incidence and outcomes of women with non-Hodgkin\u2019s lymphoma in pregnancy: a population-based study on 7.9 million births. J Obstet Gynaecol Res. 2015;41(4):582\u20139.","journal-title":"J Obstet Gynaecol Res"},{"issue":"7","key":"972_CR8","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/S1470-2045(12)70589-2","volume":"14","author":"NA Horowitz","year":"2013","unstructured":"Horowitz NA, Benyamini N, Wohlfart K, Brenner B, Avivi I. Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review. Lancet Oncol. 2013;14(7):e275\u201382.","journal-title":"Lancet Oncol"},{"key":"972_CR9","doi-asserted-by":"crossref","unstructured":"Wang PI, Chong ST, Kielar AZ, Kelly AM, Knoepp UD, Mazza MB, et al. Imaging of pregnant and lactating patients: part 2, evidence-based review and recommendations. Am J Roentgenol. 2012;198(4):785\u201392.","DOI":"10.2214\/AJR.11.8223"},{"issue":"1","key":"972_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0029-7844(96)00095-6","volume":"88","author":"PG Whittaker","year":"1996","unstructured":"Whittaker PG, Macphail S, Lind T. Serial hematologic changes and pregnancy outcome. Obstet Gynecol. 1996;88(1):33\u20139.","journal-title":"Obstet Gynecol"},{"key":"972_CR11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bpobgyn.2015.10.005","volume":"33","author":"J de Haan","year":"2016","unstructured":"de Haan J, Vandecaveye V, Han SN, Van de Vijver KK, Amant F. Difficulties with diagnosis of malignancies in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33:19\u201332.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"10","key":"972_CR12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/jp.2011.172","volume":"32","author":"JS Brandt","year":"2012","unstructured":"Brandt JS, Fishman S, Magro CM. Cutaneous melanoma arising from a cesarean delivery skin scar. J Perinatol. 2012;32(10):807\u20139.","journal-title":"J Perinatol"},{"issue":"4","key":"972_CR13","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.suronc.2011.06.002","volume":"20","author":"E Voulgaris","year":"2011","unstructured":"Voulgaris E, Pentheroudakis G, Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg Oncol. 2011;20(4):e175\u2013e85.","journal-title":"Surg Oncol"},{"issue":"5","key":"972_CR14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ejh.12956","volume":"99","author":"Y Moshe","year":"2017","unstructured":"Moshe Y, Bentur OS, Lishner M, Avivi I. The management of Hodgkin lymphomas in pregnancies. Eur J Haematol. 2017;99(5):385\u201391.","journal-title":"Eur J Haematol"},{"issue":"3","key":"972_CR15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.amjsurg.2005.03.033","volume":"190","author":"R Cohen-Kerem","year":"2005","unstructured":"Cohen-Kerem R, Railton C, Oren D, Lishner M, Koren G. Pregnancy outcome following non-obstetric surgical intervention. Am J Surg. 2005;190(3):467\u201373.","journal-title":"Am J Surg"},{"issue":"6","key":"972_CR16","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/AOG.0b013e3181c2bde8","volume":"114","author":"M Abbassi-Ghanavati","year":"2009","unstructured":"Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol. 2009;114(6):1326\u201331.","journal-title":"Obstet Gynecol"},{"key":"972_CR17","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201367.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"972_CR18","doi-asserted-by":"crossref","unstructured":"\u2022 Takalkar AM, Khandelwal A, Lokitz S, Lilien DL, Stabin MG. 18F-FDG PET in pregnancy and fetal radiation dose estimates. J Nucl Med. 2011;52(7):1035\u201340. This study estimated fetal radiation exposure resulting from 18F-FDG PET in pregnant patients and found radiation exposure to be siginificantly below the threshold dose for causing adverse fetal effects.","DOI":"10.2967\/jnumed.110.085381"},{"issue":"1","key":"972_CR19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/AOG.0000000000003049","volume":"133","author":"C Jain","year":"2019","unstructured":"Jain C. ACOG Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol. 2019;133(1):186.","journal-title":"Obstet Gynecol"},{"key":"972_CR20","doi-asserted-by":"crossref","unstructured":"\u2022 Gjelsteen AC, Ching BH, Meyermann MW, Prager DA, Murphy TF, Berkey BD, et al. CT, MRI, PET, PET\/CT, and ultrasound in the evaluation of obstetric and gynecologic patients. Surg Clin North Am. 2008;88(2):361\u201390. ACOG committee practice guidelines for recommendation regarding diagnostic imaging procedures during pregnancy with emphasis on not witholding adequate imaging from a pregnant patient.vii.","DOI":"10.1016\/j.suc.2008.01.005"},{"issue":"1","key":"972_CR21","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/esmoopen-2015-000017","volume":"1","author":"R Woitek","year":"2016","unstructured":"Woitek R, Prayer D, Hojreh A, Helbich T. Radiological staging in pregnant patients with cancer. ESMO open. 2016;1(1):e000017.","journal-title":"ESMO open"},{"issue":"4","key":"972_CR22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1148\/rg.274065149","volume":"27","author":"CH McCollough","year":"2007","unstructured":"McCollough CH, Schueler BA, Atwell TD, Braun NN, Regner DM, Brown DL, et al. Radiation exposure and pregnancy: when should we be concerned? Radiographics. 2007;27(4):909\u201317.","journal-title":"Radiographics"},{"key":"972_CR23","doi-asserted-by":"crossref","unstructured":"Kanal KM, Krupinski E, Berns EA, Geiser WR, Karellas A, Mainiero MB, et al. ACR-AAPM-SIIM practice guideline for determinants of image quality in digital mammography. J Digit Imaging. 2013;26(1):10\u201325.","DOI":"10.1007\/s10278-012-9521-3"},{"key":"972_CR24","doi-asserted-by":"crossref","unstructured":"\u2022 Rimawi BH, Green V, Lindsay M. Fetal implications of diagnostic radiation exposure during pregnancy: evidence-based recommendations. Clin Obstet Gynecol. 2016;59(2):412\u20138. Review of radation doses associated with fetal risk and radiation doses from radiologic studies and evidenced based recommendations for diagnostic radigraphic studies during pregnancy.","DOI":"10.1097\/GRF.0000000000000187"},{"key":"972_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol. 2004;15(1):146\u201350. Analysis of 160 patient pregnancies exposed to anthracyclines which determined that the risk of embryo-fetal toxicity is low, especially if exposure is after the first trimester using doses below 70 mg\/m2.","DOI":"10.1093\/annonc\/mdh009"},{"key":"972_CR26","doi-asserted-by":"crossref","unstructured":"van Hasselt J, Allegaert K, Van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Res Int. 2014;2014.","DOI":"10.1155\/2014\/897216"},{"key":"972_CR27","doi-asserted-by":"crossref","unstructured":"\u2022 Cardonick EH, Gringlas MB, Hunter K, Greenspan J. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015;212(5):658. e1\u2013e8. This study performed developmental testing on children exposed to in utero chemotherapy and found no significant differences in cognitive skills, academic achievement, or behavioral compentence between the exposed and unexposed groups.","DOI":"10.1016\/j.ajog.2014.11.032"},{"key":"972_CR28","doi-asserted-by":"crossref","unstructured":"\u2022 Van Calsteren K, Verbesselt R, Ottevanger N, Halaska M, Heyns L, Van Bree R, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010;89(10):1338\u201345. This study evaluates the impact of physiologic changes of pregnancy on the pharmacokinestics of chemotherapeutic agents between pregnant and nonpregnat state.","DOI":"10.3109\/00016349.2010.512070"},{"issue":"5","key":"972_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2014.06.004","volume":"28","author":"I Avivi","year":"2014","unstructured":"Avivi I, Farbstein D, Brenner B, Horowitz NA. Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. Blood Rev. 2014;28(5):213\u201320.","journal-title":"Blood Rev"},{"issue":"5","key":"972_CR30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1470-2045(04)01466-4","volume":"5","author":"E Cardonick","year":"2004","unstructured":"Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283\u201391.","journal-title":"Lancet Oncol"},{"issue":"4","key":"972_CR31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/bdrb.20201","volume":"86","author":"N Pent\u0161uk","year":"2009","unstructured":"Pent\u0161uk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res Part B: Dev Reprod Toxicol. 2009;86(4):328\u201344.","journal-title":"Birth Defects Res Part B: Dev Reprod Toxicol"},{"key":"972_CR32","doi-asserted-by":"crossref","unstructured":"Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, et al. Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy. JAMA Oncology. 2016;2(8):1065\u20139.","DOI":"10.1001\/jamaoncol.2016.1396"},{"issue":"11","key":"972_CR33","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/ijc.27560","volume":"131","author":"A Aviles","year":"2012","unstructured":"Aviles A, Neri N, Nambo MJ. Hematological malignancies and pregnancy: treat or no treat during first trimester. Int J Cancer. 2012;131(11):2678\u201383.","journal-title":"Int J Cancer"},{"issue":"suppl_6","key":"972_CR34","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","volume":"24","author":"FA Peccatori","year":"2013","unstructured":"Peccatori FA, Azim H Jr, Orecchia R, Hoekstra H, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi160\u2013vi70.","journal-title":"Ann Oncol"},{"key":"972_CR35","doi-asserted-by":"crossref","unstructured":"\u2022 Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013;31(32):4132\u20139. Largest multicenter study to date of 90 patients with lymphoma diagnosed during pregnancy which found no significant increase in maternal or fetal complications in the women receiving antenatal chemotherapy given as early at 13 weeks of gestation.","DOI":"10.1200\/JCO.2013.49.8220"},{"issue":"11","key":"972_CR36","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2352-3026(19)30195-4","volume":"6","author":"C Maggen","year":"2019","unstructured":"Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, Smakov R, et al. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol. 2019;6(11):e551\u2013e61.","journal-title":"Lancet Haematol"},{"key":"972_CR37","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, et al. NCCN guidelines insights: Hodgkin lymphoma, version 1.2018. J Natl Compr Cancer Netw. 2018;16(3):245\u201354."},{"issue":"5","key":"972_CR38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PPO.0000000000000333","volume":"24","author":"JM Connors","year":"2018","unstructured":"Connors JM. Advanced-stage Hodgkin lymphoma: new approaches based on novel therapeutic agents or treatment intensification. Cancer J. 2018;24(5):230\u20136.","journal-title":"Cancer J"},{"key":"972_CR39","unstructured":"Dose FR. Adcetris\u00ae(brentuximab vedotin). Specialty Drug Utilization Criteria. 2017;14."},{"issue":"9815","key":"972_CR40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(11)61348-2","volume":"379","author":"B Brenner","year":"2012","unstructured":"Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815):580\u20137.","journal-title":"Lancet"},{"key":"972_CR41","doi-asserted-by":"crossref","unstructured":"\u2022 Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors. Cancer Treat Rev. 2010;36(2):110\u201321. Systematic review of women with hematologic malignancies, including lymphoma, that explores the safety of different systemic regimens and proposes alternativves to standardized approaches in the setting of increased risk to the pregnancy and\/or fetus.","DOI":"10.1016\/j.ctrv.2009.11.004"},{"issue":"5","key":"972_CR42","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/bjh.13327","volume":"169","author":"TA Eyre","year":"2015","unstructured":"Eyre TA, Lau IJ, Mackillop L, Collins GP. Management and controversies of classical Hodgkin lymphoma in pregnancy. Br J Haematol. 2015;169(5):613\u201330.","journal-title":"Br J Haematol"},{"issue":"3","key":"972_CR43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11899-013-0163-4","volume":"8","author":"V Bachanova","year":"2013","unstructured":"Bachanova V, Connors JM. Hodgkin lymphoma in pregnancy. Curr Hematol Malig Rep. 2013;8(3):211\u20137.","journal-title":"Curr Hematol Malig Rep"},{"key":"972_CR44","doi-asserted-by":"crossref","unstructured":"Avil\u00e8s A, Nambo M-J, Neri N. Treatment of early stages hodgkin lymphoma during pregnancy. Mediterr J Hematol infect Dis. 2018;10(1).","DOI":"10.4084\/mjhid.2018.006"},{"issue":"2","key":"972_CR45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00404-012-2287-5","volume":"286","author":"E-S Abdel-Hady","year":"2012","unstructured":"Abdel-Hady E-S, Hemida RA-H, Gamal A, El-Zafarany M, Toson E, El-Bayoumi MA. Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy. Arch Gynecol Obstet. 2012;286(2):283\u20136.","journal-title":"Arch Gynecol Obstet"},{"key":"972_CR46","doi-asserted-by":"crossref","unstructured":"Hay A, Klimm B, Chen B, Goergen H, Shepherd L, Fuchs M, et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2013;24(12):3065\u20139.","DOI":"10.1093\/annonc\/mdt389"},{"issue":"3","key":"972_CR47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0167-8140(02)00329-8","volume":"66","author":"M Mazonakis","year":"2003","unstructured":"Mazonakis M, Varveris H, Fasoulaki M, Damilakis J. Radiotherapy of Hodgkin\u2019s disease in early pregnancy: embryo dose measurements. Radiother Oncol. 2003;66(3):333\u20139.","journal-title":"Radiother Oncol"},{"issue":"5","key":"972_CR48","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(05)70169-8","volume":"6","author":"HB Kal","year":"2005","unstructured":"Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6(5):328\u201333.","journal-title":"Lancet Oncol"},{"issue":"2","key":"972_CR49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0360-3016(92)90761-6","volume":"23","author":"SY Woo","year":"1992","unstructured":"Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, et al. Radiotherapy during pregnancy for clinical stages IA\u2013IIA Hodgkin\u2019s disease. Int J Radiat Oncol Biol Phys. 1992;23(2):407\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"972_CR50","doi-asserted-by":"crossref","unstructured":"Cousins C. Medical radiation and pregnancy. Health Physics 2008;95(5).","DOI":"10.1097\/01.HP.0000327647.74948.49"},{"issue":"4","key":"972_CR51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00330-015-3924-8","volume":"26","author":"S Woussen","year":"2016","unstructured":"Woussen S, Lopez-Rendon X, Vanbeckevoort D, Bosmans H, Oyen R, Zanca F. Clinical indications and radiation doses to the conceptus associated with CT imaging in pregnancy: a retrospective study. Eur Radiol. 2016;26(4):979\u201385.","journal-title":"Eur Radiol"},{"issue":"1","key":"972_CR52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bjc.1992.21","volume":"65","author":"M Lishner","year":"1992","unstructured":"Lishner M, Zemlickis D, Degendorfer P, Panzarella T, Sutcliffe S, Koren G. Maternal and foetal outcome following Hodgkin\u2019s disease in pregnancy. Br J Cancer. 1992;65(1):114\u20137.","journal-title":"Br J Cancer"},{"issue":"9","key":"972_CR53","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3324\/haematol.11097","volume":"92","author":"D Pereg","year":"2007","unstructured":"Pereg D, Koren G, Lishner M. The treatment of Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma in pregnancy. Haematologica. 2007;92(9):1230\u20137.","journal-title":"Haematologica."},{"issue":"3","key":"972_CR54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/WHE.14.17","volume":"10","author":"N Lavi","year":"2014","unstructured":"Lavi N, Horowitz NA, Brenner B. An update on the management of hematologic malignancies in pregnancy. Womens Health (Lond). 2014;10(3):255\u201366.","journal-title":"Womens Health (Lond)"},{"key":"972_CR55","doi-asserted-by":"crossref","unstructured":"Odelia A, Erel J, Chava P, Yair H, Nadav S, Michael L, et al. Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire. Int J Clin Oncol. 2017;22(1):190\u20139.","DOI":"10.1007\/s10147-016-1036-3"},{"key":"972_CR56","doi-asserted-by":"crossref","unstructured":"\u2022 Avil\u00e9s A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clinical Lymphoma. 2001;2(3):173\u20137. Acute and late side effects were evaluated in 84 children whose mothers received chemoterahyp during pregnancy, including 38 during the first trimester over a median of 18.7 years, and no increased risk of adverse pediatric outcomes, including secondary malignancies.","DOI":"10.3816\/CLM.2001.n.023"},{"issue":"12","key":"972_CR57","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ajh.21547","volume":"84","author":"T Rizack","year":"2009","unstructured":"Rizack T, Mega A, Legare R, Castillo J. Management of hematological malignancies during pregnancy. Am J Hematol. 2009;84(12):830\u201341.","journal-title":"Am J Hematol"},{"issue":"4","key":"972_CR58","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/GRF.0b013e318236e68a","volume":"54","author":"JB Cohen","year":"2011","unstructured":"Cohen JB, Blum KA. Evaluation and management of lymphoma and leukemia in pregnancy. Clin Obstet Gynecol. 2011;54(4):556\u201366.","journal-title":"Clin Obstet Gynecol"},{"issue":"5","key":"972_CR59","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","volume":"117","author":"EF Chakravarty","year":"2011","unstructured":"Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499\u2013506.","journal-title":"Blood."},{"key":"972_CR60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4137\/CMO.S6085","volume":"5","author":"N Tageja","year":"2011","unstructured":"Tageja N. Bendamustine: safety and efficacy in the management of indolent non-Hodgkin\u2019s lymphoma. Clin Med Insights Oncol. 2011;5:145\u201356.","journal-title":"Clin Med Insights Oncol"},{"issue":"9873","key":"972_CR61","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet."},{"issue":"4","key":"972_CR62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ogc.2005.08.009","volume":"32","author":"KK Leslie","year":"2005","unstructured":"Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin N Am. 2005;32(4):627\u201340.","journal-title":"Obstet Gynecol Clin N Am"},{"issue":"3","key":"972_CR63","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","volume":"5","author":"G Das","year":"2018","unstructured":"Das G, Damotte V, Gelfand JM, Bevan C, Cree BA, Do L, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol-Neuroimmunol Neuroinflammation. 2018;5(3):e453.","journal-title":"Neurol-Neuroimmunol Neuroinflammation"},{"issue":"19","key":"972_CR64","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","volume":"124","author":"C Jacobson","year":"2014","unstructured":"Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. Blood. 2014;124(19):2913\u201320.","journal-title":"Blood."},{"key":"972_CR65","first-page":"370179","volume":"2013","author":"C Zagalo","year":"2013","unstructured":"Zagalo C, Pierdomenico F, Cabecadas J, David SP. Burkitt\u2019s lymphoma in a pregnant woman: case report and review of the literature. Case Rep Oncol Med. 2013;2013:370179.","journal-title":"Case Rep Oncol Med"},{"issue":"11","key":"972_CR66","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1345\/aph.1H289","volume":"40","author":"MS Lam","year":"2006","unstructured":"Lam MS. Treatment of Burkitt\u2019s lymphoma during pregnancy. Ann Pharmacother. 2006;40(11):2048\u201352.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"972_CR67","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1200\/JCO.2009.24.6355","volume":"28","author":"C Peterson","year":"2010","unstructured":"Peterson C, Lester DR Jr, Sanger W. Burkitt\u2019s lymphoma in early pregnancy. J Clin Oncol. 2010;28(9):e136\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"972_CR68","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/qjmed\/92.10.551","volume":"92","author":"M Lloyd","year":"1999","unstructured":"Lloyd M, Carr M, McElhatton P, Hall G, Hughes R. The effects of methotrexate on pregnancy, fertility and lactation. Qjm. 1999;92(10):551\u201363.","journal-title":"Qjm."},{"issue":"3","key":"972_CR69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/tera.1420170314","volume":"17","author":"J Warkany","year":"1978","unstructured":"Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology. 1978;17(3):353\u20137.","journal-title":"Teratology."},{"issue":"4","key":"972_CR70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/bdra.23003","volume":"94","author":"SC Hyoun","year":"2012","unstructured":"Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94(4):187\u2013207.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"9","key":"972_CR71","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/ajmg.a.36625","volume":"164A","author":"AL Dawson","year":"2014","unstructured":"Dawson AL, Riehle-Colarusso T, Reefhuis J, Arena JF, National Birth Defects Prevention S. Maternal exposure to methotrexate and birth defects: a population-based study. Am J Med Genet A. 2014;164A(9):2212\u20136.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"972_CR72","first-page":"4","volume":"18","author":"G Koren","year":"2013","unstructured":"Koren G. Treating the mother, protecting the unborn: the motherisk approach. J Pediatr Pharmacol Ther. 2013;18(1):4\u20137.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"972_CR73","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/keh612","volume":"44","author":"M Lloyd","year":"2005","unstructured":"Lloyd M, McElhatton P, Carr M, Hall G, Hughes R. Methotrexate in pregnancy. Rheumatology (Oxford). 2005;44(5):697 author reply 8.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"972_CR74","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11899-017-0386-x","volume":"12","author":"CC Pinnix","year":"2017","unstructured":"Pinnix CC, Andraos TY, Milgrom S, Fanale MA. The management of lymphoma in the setting of pregnancy. Curr Hematol Malig Rep. 2017;12(3):251\u20136.","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"972_CR75","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1471-0528.2004.00236.x","volume":"111","author":"A Einarson","year":"2004","unstructured":"Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG Int J Obstet Gynaecol. 2004;111(9):940\u20133.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"9","key":"972_CR76","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1056\/NEJMoa1211035","volume":"368","author":"B Pasternak","year":"2013","unstructured":"Pasternak B, Svanstr\u00f6m H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368(9):814\u201323.","journal-title":"N Engl J Med"},{"issue":"24","key":"972_CR77","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1056\/NEJMoa0807154","volume":"360","author":"I Matok","year":"2009","unstructured":"Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med. 2009;360(24):2528\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"972_CR78","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00228-005-0055-1","volume":"61","author":"C Asker","year":"2005","unstructured":"Asker C, Wikner BN, K\u00e4ll\u00e9n B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol. 2005;61(12):899\u2013906.","journal-title":"Eur J Clin Pharmacol"},{"key":"972_CR79","doi-asserted-by":"crossref","unstructured":"Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423\u201331.","DOI":"10.1007\/s00520-009-0680-9"},{"issue":"11","key":"972_CR80","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00128072-200103110-00003","volume":"3","author":"A Einarson","year":"2001","unstructured":"Einarson A, Shuhaiber S, Koren G. Effects of antibacterials on the unborn child. Paediatric Drugs. 2001;3(11):803\u201316.","journal-title":"Paediatric Drugs"},{"key":"972_CR81","doi-asserted-by":"crossref","unstructured":"American College of O, Gynecologists Committee on Obstetric P. ACOG Committee opinion no. 494: sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol 2011;117(6):1484\u20131485.","DOI":"10.1097\/AOG.0b013e3182238c57"},{"issue":"5","key":"972_CR82","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/01.AOG.0000216197.26783.b5","volume":"107","author":"GG Nahum","year":"2006","unstructured":"Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107(5):1120\u201338.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"972_CR83","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jama.2010.1206","volume":"304","author":"B Pasternak","year":"2010","unstructured":"Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. Jama. 2010;304(8):859\u201366.","journal-title":"Jama."},{"issue":"1","key":"972_CR84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jac\/dku355","volume":"70","author":"B Pilmis","year":"2014","unstructured":"Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother. 2014;70(1):14\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"972_CR85","doi-asserted-by":"crossref","unstructured":"Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003;72(2):82\u201393.","DOI":"10.1002\/ajh.10255"},{"key":"972_CR86","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2147\/IJWH.S52381","volume":"6","author":"E Cardonick","year":"2014","unstructured":"Cardonick E. Pregnancy-associated breast cancer: optimal treatment options. Int J Women's Health. 2014;6:935\u201343.","journal-title":"Int J Women's Health"},{"issue":"10","key":"972_CR87","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1160\/TH16-02-0099","volume":"116","author":"NA Horowitz","year":"2016","unstructured":"Horowitz NA, Lavi N, Nadir Y, Brenner B. Haematological malignancies in pregnancy: an overview with an emphasis on thrombotic risks. Thromb Haemost. 2016;116(10):613\u20137.","journal-title":"Thromb Haemost"},{"issue":"6","key":"972_CR88","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMcp1407434","volume":"373","author":"IA Greer","year":"2015","unstructured":"Greer IA. Clinical practice. Pregnancy complicated by venous thrombosis. N Engl J Med. 2015;373(6):540\u20137.","journal-title":"N Engl J Med"},{"key":"972_CR89","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0049-3848(12)70011-7","volume":"129","author":"B Brenner","year":"2012","unstructured":"Brenner B, Avivi I. Cancer in pregnancy: the role of thromboprophylaxis. Thromb Res. 2012;129:S20\u2013S1.","journal-title":"Thromb Res"},{"key":"972_CR90","doi-asserted-by":"crossref","unstructured":"\u2022 Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13(3):256\u201364. Multicenter observational cohort of 129 children born pregnant women exposed to chemotherapy matched to children of unexposed mothers without cancer, which recorded the health, cardiac function, and neurodevelopmental outcomes of children exposed to in untero chemotherapy.","DOI":"10.1016\/S1470-2045(11)70363-1"},{"issue":"2","key":"972_CR91","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/10428194.2017.1352097","volume":"59","author":"K Shliakhtsitsava","year":"2018","unstructured":"Shliakhtsitsava K, Romero SA, Dewald SR, Su HI. Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review. Leuk Lymphoma. 2018;59(2):381\u201397.","journal-title":"Leuk Lymphoma"},{"key":"972_CR92","doi-asserted-by":"crossref","unstructured":"Weibull CE, Eloranta S, Smedby KE, Bj\u00f6rkholm M, Kristinsson SY, Johansson AL, et al. Pregnancy and the risk of relapse in patients diagnosed with Hodgkin lymphoma. J Clin Oncol. 2015;34(4):337\u201344.","DOI":"10.1200\/JCO.2015.63.3446"},{"key":"972_CR93","doi-asserted-by":"crossref","unstructured":"Maltaris T, Seufert R, Fischl F, Schaffrath M, Pollow K, Koelbl H, et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol. 2007;130(2):148\u201355.","DOI":"10.1016\/j.ejogrb.2006.08.006"},{"issue":"1\u20132","key":"972_CR94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10428199909093726","volume":"33","author":"D Meirow","year":"1999","unstructured":"Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma. 1999;33(1\u20132):65\u201376.","journal-title":"Leuk Lymphoma"},{"key":"972_CR95","doi-asserted-by":"crossref","unstructured":"Hodgson DC, Pintilie M, Gitterman L, DeWitt B, Buckley CA, Ahmed S, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25(1):11\u20135.","DOI":"10.1002\/hon.802"},{"key":"972_CR96","doi-asserted-by":"crossref","unstructured":"Anderson RA, Brewster DH, Wood R, Nowell S, Fischbacher C, Kelsey TW, et al. The impact of cancer on subsequent chance of pregnancy: a population-based analysis. Hum Reprod. 2018;33(7):1281\u201390.","DOI":"10.1093\/humrep\/dey216"},{"key":"972_CR97","doi-asserted-by":"crossref","unstructured":"Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231\u20139.","DOI":"10.1200\/JCO.2012.44.3721"},{"issue":"1","key":"972_CR98","first-page":"27","volume":"18","author":"JV Medrano","year":"2020","unstructured":"Medrano JV, Lujan S, Andres MDM, Pellicer A. Current state regarding fertility cryopreservation in pre-pubertal boys. Rev Int Androl. 2020;18(1):27\u201334.","journal-title":"Rev Int Androl"},{"issue":"6","key":"972_CR99","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/humupd\/7.6.535","volume":"7","author":"D Meirow","year":"2001","unstructured":"Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535\u201343.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"972_CR100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/sj.thj.6200248","volume":"4","author":"P Franchi-Rezgui","year":"2003","unstructured":"Franchi-Rezgui P, Rousselot P, Espie M, Briere J, Pierre Marolleau J, Gisselbrecht C, et al. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J. 2003;4(2):116\u201320.","journal-title":"Hematol J"},{"issue":"5","key":"972_CR101","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11912-002-0039-6","volume":"4","author":"SJ Howell","year":"2002","unstructured":"Howell SJ, Shalet SM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep. 2002;4(5):443\u201352.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"972_CR102","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejogrb.2012.10.026","volume":"167","author":"SN Han","year":"2013","unstructured":"Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F, Force ECiPT. Cancer in pregnancy: a survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):18\u201323.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"972_CR103","doi-asserted-by":"crossref","unstructured":"\u2022 Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373(19):1824\u201334. Multicenter case-control prospective study in which children exposed to in utero chemotherapy were compared with matched children of women without a cancer diagnosis, there was no icnreased impairment in cognitive, cardic, or general development in early childhood. However, iatrogenic prematurity was correlated with a worse cognitive outcome, independent of cancer diagnosis.","DOI":"10.1056\/NEJMoa1508913"},{"issue":"6","key":"972_CR104","doi-asserted-by":"crossref","first-page":"526","DOI":"10.5468\/ogs.2014.57.6.526","volume":"57","author":"EJ Lee","year":"2014","unstructured":"Lee EJ, Ahn KH, Hong SC, Lee EH, Park Y, Kim BS. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth. Obstet Gynecol Sci. 2014;57(6):526\u20139.","journal-title":"Obstet Gynecol Sci"},{"issue":"2","key":"972_CR105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdj053","volume":"17","author":"A Avil\u00e9s","year":"2006","unstructured":"Avil\u00e9s A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol. 2006;17(2):286\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"972_CR106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2015.09.009","volume":"16","author":"A Avil\u00e8s","year":"2016","unstructured":"Avil\u00e8s A, Nambo M-J, Huerta-Guzm\u00e0n J, Neri N, Cleto S. Speckle-tracking echocardiography to detect cardiac toxicity in children who received anthracyclines during pregnancy. Clin Lymphoma Myeloma Leuk. 2016;16(1):1\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"972_CR107","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10815-012-9786-y","volume":"29","author":"IP Committee","year":"2012","unstructured":"Committee IP, Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29(6):465\u20138.","journal-title":"J Assist Reprod Genet"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-020-00972-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:16:22Z","timestamp":1629159382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-020-00972-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":107,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-00972-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"17 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Mansi R. Shah, Justin S. Brandt, and Kevin A. David declare that they have no conflict of interest. Andrew M. Evens: Advisory Board with honorarium: Seattle Genetics, MorphoSys, Mylteni, Karyopharm, and Epizyme; Consultant with honorarium: Novartis, Abvie and Pharmacyclics; Speakers bureau: Research To Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"113"}}